Pfizer (NYSE:PFE – Get Free Report) had its price objective lowered by investment analysts at BMO Capital Markets from $34.00 to $30.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target suggests a potential upside of 23.89% from the stock’s previous close.
Several other analysts have also recently issued reports on PFE. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Guggenheim cut their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a report on Monday. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.50.
Read Our Latest Research Report on Pfizer
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the company earned $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer will post 2.96 EPS for the current year.
Hedge Funds Weigh In On Pfizer
Several institutional investors and hedge funds have recently made changes to their positions in PFE. Horizon Financial Services LLC grew its stake in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the 4th quarter valued at about $28,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Recommended Stories
- Five stocks we like better than Pfizer
- 3 Dividend Stocks with Growth on Tap for the Second Half
- 3 Overlooked Stocks Positioned for the Next Market Rotation
- 3 Non-Tech Stocks Still Winning Big on AI
- Achieve Robust Diversification With These 3 Equal-Weight ETFs
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
